eligibility_summary
Adults (≥18) with measurable RAI‑refractory DTC (progressed after ≥1 approved therapy, ≤3 lines) or ATC (1L or ≤1 prior line). ECOG 0–1, tissue available, adequate counts/organ function. Contraception per protocol, no other interventional study. Exclude CNS mets, unresolved ≥G2 toxicities, recent/active second cancer, active HBV/HCV/HIV, significant cardiac/cerebrovascular/respiratory/GI disease, uncontrolled HTN/DM, recent RT/surgery/live vaccine/antibiotics/systemic therapy, prior topo‑I, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06235216 (SETHY) tests sacituzumab govitecan (Trodelvy), an antibody-drug conjugate: a humanized anti-TROP-2 monoclonal antibody linked to SN-38 (the active metabolite of irinotecan). Indications: advanced RAI-refractory differentiated thyroid cancer and anaplastic thyroid cancer. Mechanism: the antibody binds TROP-2 on tumor cell membranes, is internalized, and releases SN-38 to inhibit topoisomerase I, causing DNA damage, replication stress, and tumor cell death, SN-38 can produce a bystander effect. Targets: TROP-2–overexpressing thyroid cancer cells and the DNA replication/repair pathway via topoisomerase I inhibition.